title: Heart valve engineering: decellularized allograft matrices in clinical practice.
abstract: The purpose of this review is to update the current clinical experience with tissue-engineered, nonseeded, allogenic matrices for pulmonary and aortic valve replacement. Allogenic heart valve replacement using an aortic root homograft was first performed 50 years ago on July 24, 1962, by Donald Ross at Guy's Hospital, London. Cryopreserved homografts have been the gold standard for many years in selected indications such as for pulmonary valve replacement in congenital heart disease, severe bacterial endocarditis, or for right ventricular outflow tract reconstruction during the Ross pulmonary autograft operation. However, there is evolving evidence that tissue-engineered decellularized homografts may be superior to conventional cryopreserved homografts.
authors.forename: Anneke
authors.initials: A
authors.lastname: Neumann
authors.forename: Serghei
authors.initials: S
authors.lastname: Cebotari
authors.forename: Igor
authors.initials: I
authors.lastname: Tudorache
authors.forename: Axel
authors.initials: A
authors.lastname: Haverich
authors.forename: Samir
authors.initials: S
authors.lastname: Sarikouch
mesh_terms: D000818:Animals; D001705:Bioprosthesis; D002474:Cell-Free System; D006349:Heart Valve Diseases / Q000601:surgery*; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000379:methods*; D006801:Humans; D011474:Prosthesis Design; D023822:Tissue Engineering / Q000295:instrumentation*; D054457:Tissue Scaffolds